Wang XX - Search Results

1

Identification and Therapeutic Targeting of METTL8-Mediated Lenvatinib Resistance in Hepatocellular Carcinoma Using Rabdosiin.

Liu Y, Chen M, Wang XX, Gao Y, Han X, Wang S, Zhang W, Lei X, Yu P, Liu L, Zhang HM, Zhang K. Liu Y, et al. Among authors: wang xx. Exp Cell Res. 2024 Dec 17:114389. doi: 10.1016/j.yexcr.2024.114389. Online ahead of print. Exp Cell Res. 2024. PMID: 39701355

2

CXCL12⁺ Tumor-associated Endothelial Cells Promote Immune Resistance in Hepatocellular Carcinoma.

Lu Y, Liu Y, Zuo X, Li G, Wang J, Liu J, Wang X, Wang S, Zhang W, Zhang K, Lei X, Hao Q, Li W, Liu L, Li M, Zhang C, Zhang H, Zhang Y, Gao Y. Lu Y, et al. J Hepatol. 2024 Oct 9:S0168-8278(24)02618-7. doi: 10.1016/j.jhep.2024.09.044. Online ahead of print. J Hepatol. 2024. PMID: 39393439

3

Stratifying hepatocellular carcinoma based on immunophenotypes for immunotherapy response and prognosis.

Liu Y, Ji H, Wu LH, Wang XX, Yang Y, Zhang Q, Zhang HM. Liu Y, et al. Among authors: wang xx. Mol Ther Oncol. 2024 Oct 5;32(4):200890. doi: 10.1016/j.omton.2024.200890. eCollection 2024 Dec 19. Mol Ther Oncol. 2024. PMID: 39498358 Free PMC article.

4

The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma.

Liu QQ, Wang XX, Ji H, Dou QY, Zhang HM. Liu QQ, et al. Among authors: wang xx. Med Oncol. 2024 Mar 25;41(5):91. doi: 10.1007/s12032-024-02309-5. Med Oncol. 2024. PMID: 38526607

5

Exploration of the Tumor Immune Landscape and Identification of Two Novel Immunotherapy-Related Genes for Epstein-Barr virus-associated Gastric Carcinoma via Integrated Bioinformatics Analysis.

Deng SZ, Wang XX, Zhao XY, Bai YM, Zhang HM. Deng SZ, et al. Among authors: wang xx. Front Surg. 2022 May 23;9:898733. doi: 10.3389/fsurg.2022.898733. eCollection 2022. Front Surg. 2022. PMID: 36090326 Free PMC article.

6

Identifying specific TLS-associated genes as potential biomarkers for predicting prognosis and evaluating the efficacy of immunotherapy in soft tissue sarcoma.

Wang XX, Liu YP, Lu Y, Wu LH, Ren JY, Ji H, Wang X, Zhang HM. Wang XX, et al. Among authors: wang x. Front Immunol. 2024 Apr 24;15:1372692. doi: 10.3389/fimmu.2024.1372692. eCollection 2024. Front Immunol. 2024. PMID: 38720884 Free PMC article.

7

Construction of an HCC recurrence model basedon the investigation of immune-relatedlncRNAs and related mechanisms.

Wang XX, Wu LH, Ai L, Pan W, Ren JY, Zhang Q, Zhang HM. Wang XX, et al. Mol Ther Nucleic Acids. 2021 Nov 10;26:1387-1400. doi: 10.1016/j.omtn.2021.11.006. eCollection 2021 Dec 3. Mol Ther Nucleic Acids. 2021. PMID: 34900397 Free PMC article.

8

Construction of m6A-based prognosis signature and prediction for immune and anti-angiogenic response.

Wang XX, Wu LH, Dou QY, Ai L, Lu Y, Deng SZ, Liu QQ, Ji H, Zhang HM. Wang XX, et al. Front Mol Biosci. 2022 Oct 21;9:1034928. doi: 10.3389/fmolb.2022.1034928. eCollection 2022. Front Mol Biosci. 2022. PMID: 36339715 Free PMC article.

9

Predicting TCR sequences for unseen antigen epitopes using structural and sequence features.

Ji H, Wang XX, Zhang Q, Zhang C, Zhang HM. Ji H, et al. Among authors: wang xx. Brief Bioinform. 2024 Mar 27;25(3):bbae210. doi: 10.1093/bib/bbae210. Brief Bioinform. 2024. PMID: 38711371 Free PMC article.

10

A novel cuproptosis-related prognostic signature and potential value in HCC immunotherapy.

Wang XX, Wu LH, Ji H, Liu QQ, Deng SZ, Dou QY, Ai L, Pan W, Zhang HM. Wang XX, et al. Front Mol Biosci. 2022 Sep 29;9:1001788. doi: 10.3389/fmolb.2022.1001788. eCollection 2022. Front Mol Biosci. 2022. PMID: 36250008 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,731 results

Search Page

Filters